Celgene Whacked After Blood-Drug Regimen Fails In Phase 3 Trial

Shutterstock photo

Celgene ( CELG ) toppled late Thursday after its drug regimen failed in a Phase 3 study of patients with a form of non-Hodgkin lymphoma.

[ibd-display-video id=3037425 width=50 float=left autostart=true] In after-hours trading on the stock market today , Celgene dove 4.5%, near 103, after closing down 0.4%, at 107.88.

The trial investigated a regimen of Revlimid plus rituximab followed by maintenance treatment with rituximab compared with the standard of care of rituximab plus chemotherapy. The regimen was tested in patients with follicular lymphoma.

Revlimid is Celgene's blockbuster blood cancer drug. Rituximab is sold under the brand name, Rituxan, by Roche 's ( RHHBY ) Genentech and Biogen ( BIIB ).

The treatment didn't achieve superiority in complete response and unconfirmed complete response at 120 weeks and progression-free survival at a preplanned analysis, both key goals of the trial.


Biogen Shares Drop After Alzheimer's Drug Misses In Testing

This Biotech Stock Launched after Joining The S&P 600 SmallCap

Why These Biotech Stocks Could Be Taken Over In 2018

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Stocks
Referenced Symbols: CELG , RHHBY , BIIB

More from Investor's Business Daily


Investor's Business Daily

Investor's Business Daily


Research Brokers before you trade

Want to trade FX?